Brian Jonas, MD, Discusses FDA Approval of Venclexta® for the Treatment of Newly Diagnosed AML.

Venclexta Data Positive for AMLПодробнее

Dr. DiNardo on the Rationale for the Pooled Analysis Evaluating Venetoclax in AMLПодробнее

Venetoclax-Based Combination Therapies Revolutionize Paradigm for Elderly AMLПодробнее

Data on VENCLEXTA reinforcing the efficacyПодробнее

The importance of venetoclax in newly diagnosed AMLПодробнее

How have venetoclax combinations changed the way we treat AML?Подробнее

Dr. Lai on the Potential Benefits of Venetoclax in AMLПодробнее

Brian Jonas, ASCO20: Venetoclax combination treatment in older patients with acute myeloid leukemiaПодробнее

Venetoclax for AMLПодробнее

What is the latest on Venetoclax?Подробнее

Continued Five Year Benefit of Venetoclax Plus Rituxamab To Treat Chronic Lymphocytic LeukemiaПодробнее

Safety and efficacy of venetoclax-based regimens for AMLПодробнее

Daniel DeAngelo, MD, PhD Discusses Acute Myeloid Leukemia (Full Interview)Подробнее

The Benefits of Venetoclax in CLLПодробнее

Venclexta - week 3.Подробнее

Venetoclax retreatment for CLLПодробнее

Venetoclax: a lifesaving drug for CLL patientsПодробнее

Venetoclax + azacitidine in unfit patients with AMLПодробнее

The power of venetoclaxПодробнее